ReviewAnalytical science advances2026
Clinical Laboratory Innovations: Nanoscale Detection of Chloramphenicol Using Nanomaterial Biosensors.
Review in Analytical science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chloramphenicol (CAP) is an important broad-spectrum antibiotic used to treat severe bacterial infections, but its clinical application is limited by serious toxic effects, including aplastic anaemia and bone marrow suppression. These care concerns underscore the need for fast, sensitive and reliable analytical methods for CAP detection in biological and food samples. In recent years, nanomaterial-based biosensors have emerged as encouraging tools for this purpose, offering enhanced sensitivity, selectivity and analytical performance. This review examines recent advances in nanoscale detection of CAP using nanomaterial biosensors, with specific emphasis on nanomaterial-based electrochemical platforms. The exceptional physicochemical properties of these materials, including enhanced electron transfer, large surface area, catalytic activity and signal amplification, have contributed to the development of highly effective sensing systems. These biosensors have shown strong potential for rapid analysis and trace detection in complex matrices. Moreover, several challenges remain before these platforms can be fully translated into routine clinical and regulatory use. Subjects such as matrix effects, reproducibility, stability and validation against reference methods require further attention. This review critically discusses current progress, highlights the limitations of existing approaches and outlines future directions for the development of practical laboratory-based biosensing approaches for CAP detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.